Deciphera Pharmaceuticals, Inc.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About DCPH
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
Find out what a historical investment in Deciphera Pharmaceuticals, Inc. would be worth today using our DCPH stock calculator.
-
-
-
-
-
-
-
-
-
Ready to start your investing journey with Stake?
Open an accountDCPH FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in DCPH
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in DCPH
on Stake
Buy DCPH from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of DCPH from only US$10 with fractional shares
